Vertex Grows Its Rare Disease Business With $10bn Crinetics Buy
Vertex will pay $85 per share for Crinetics, which is double the company’s July 6 closing stock price, to acquire what it sees as a blockbuster endocrinology franchise.
Scrip - July 7, 2026

$4bn Allograft Billing Scheme Leads Wound Care Focus In DOJ’s 2026 Fraud Takedown
The US DOJ's 2026 Health Care Fraud Takedown charged 455 defendants in schemes totaling more than $6.5bn in false claims. For the medtech sector, wound care is a sustained focus: 11 defendants face charges in a $4bn Medicare allograft billing conspiracy.
Medtech Insight - July 6, 2026

Trio Of FDA Warning Letters Cites Poor Complaint Processing And Marketing Unauthorized Devices
In two separate warning letters published last week, the US FDA cited a manufacturer and a developer for marketing CPAP breathing devices without the required authorization; in a third letter from the same day, the agency rebuked a company for improperly classifying medical devices as unregulated ph
Medtech Insight - July 6, 2026

MDIC Lays Out Five-Step Cybersecurity Penetration Testing Process For Connected Device Makers
MDIC's new penetration testing guidance argues manufacturers often miscalibrate how they test connected devices and lays out a five-step framework to fix it, as regulatory submissions increasingly demand pen-test evidence.
Medtech Insight - July 6, 2026

Firms Recently Issued FDA Warning Letters Include ZOLL, Medline, Happiest Baby
The US Food and Drug Administration has posted seven warning letters in recent weeks,
Medtech Insight - July 6, 2026

EU’s AI Medtech Rules Are Set; The Machinery To Deliver Them Isn’t
EU-wide fragmentation in reimbursement, certification processes and data governance could scupper the AI Act’s single market ambitions, says a new report.
Medtech Insight - July 6, 2026

US FDA Readies Hemp Products Rule With Tighter THC Limits Imposed By Congress Approaching
Congress waits for report it requested in November 2025 identifying the varieties of cannabinoids as Nov. 12 effective date approaches for a lower limit, included in the same legislation, on all forms of THC allowed in hemp products and a ban on synthetics.
HBW Insight - July 7, 2026

Coty Initiates Organization Changes, Takasago Taps New President; Beauty Business Roundup
Coty announces structural changes that place decision-making “closer to the center,” while Japanese flavors and fragrance company Takasago names a new president and dsm-firmenich promotes two master perfumers.
HBW Insight - July 7, 2026

US Senator Presses Merck Over Keytruda Patents Limiting Biosimilar Competition
Merck’s CEO promised not to hinder biosimilar competition for its Keytruda IV. With two years left until the market opens, a US senator demands answers.
Generics Bulletin - July 6, 2026

Synthon Adds Capacity With Spanish Acquisition
Synthon has announced a significant expansion of its development and manufacturing capabilities for complex generics through the acquisition of a site adjacent to its existing Spanish operations in Sant Boi.
Generics Bulletin - July 6, 2026

Beyond Rare: Nucleic Acid Therapeutics Are Targeting The Cardiovascular Mainstream
Nucleic acid therapeutics have so far been overwhelmingly a rare-disease modality but a pipeline of more than 30 candidates is now pushing into mainstream cardiovascular indications such as hypertension, elevated lipoprotein(a), and broad dyslipidaemia.
In Vivo - July 6, 2026

Podcast: Tonix’s Bet on Monoclonal Prevention Of Lyme Disease
If approved, TNX-4800, Tonix's monoclonal antibody against Lyme disease, would offer rapid seasonal protection where vaccines have repeatedly struggled. A Phase II field study is planned for 2027.
In Vivo - July 6, 2026